June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Comparison of Hydrus Microstent and Hydrus Microstent with OMNI Canaloplasty for Mild to Moderate Primary Open Angle Glaucoma
Author Affiliations & Notes
  • Kathryn Lewis
    Department of Ophthalmology and Visual Sciences, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Camila Albo
    Department of Ophthalmology and Visual Sciences, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Aileen Wang
    Department of Ophthalmology and Visual Sciences, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Sofia Hassapis
    Department of Ophthalmology and Visual Sciences, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Corey Waldman
    Department of Ophthalmology and Visual Sciences, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Footnotes
    Commercial Relationships   Kathryn Lewis None; Camila Albo None; Aileen Wang None; Sofia Hassapis None; Corey Waldman None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4272. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kathryn Lewis, Camila Albo, Aileen Wang, Sofia Hassapis, Corey Waldman; Comparison of Hydrus Microstent and Hydrus Microstent with OMNI Canaloplasty for Mild to Moderate Primary Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4272.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Minimally invasive glaucoma surgery (MIGS) includes a variety of novel techniques to achieve lower intraocular pressure (IOP) in mild to moderate primary open angle glaucoma. The Hydrus Microstent and OMNI Surgical System are two frequently utilized devices. Recently, surgeons have employed the OMNI canaloplasty along with the Hydrus Microstent hoping to achieve additional IOP lowering. The aim of this retrospective study is to evaluate if combining OMNI canaloplasty with Hydrus Microstent improves IOP reduction and decreases drop burden compared to Hydrus alone.

Methods : This is a single-surgeon, single-center, retrospective chart review study. Data on eyes that underwent cataract surgery with Hydrus Microstenting (n=22) and Hydrus Microstenting with OMNI canaloplasty (n=20) was collected from 2020-2022. This preliminary report includes data analysis up to post-operative month 1 (POM1) given the ongoing nature of this study. Chi-squared and paired t-tests (p=0.05) were utilized.

Results : 25 patients and 42 eyes were enrolled. The average age was 68 ± 7.37 years. 11 (44%) patients were female. 12 (48%) identified at white/Caucasian, 9 (36%) as Hispanic/Latino, 2 (8%) as black/African American, and 2 (8%) as Asian. There was no significant difference in visual acuity at any time point between the Hydrus and Hydrus/OMNI groups. There was no significant difference in pre-operative IOP between the Hydrus (15.4mmHg) and OMNI/Hydrus (14.7mmHg) groups (p=0.512). There was no significant difference in IOP in either group at POM1 compared to the pre-operative IOP. The average percent decrease in IOP at POM1 was 0.015% in the Hydrus group and 0.0017% in the Hydrus/OMNI group. There was a significant difference in the average number of pre-operative IOP lowering agents between Hydrus (n=3) and Hydrus/OMNI (n=2) (p=0.004). At POM1, OMNI patients were on fewer medications (n=0) than Hydrus patients (n=2) (p=0.0002), however both groups experienced a significantly decreased drop burden at POM1 (p=0.0001 for both groups).

Conclusions : In our preliminary data analysis, the addition of OMNI canaloplasty to Hydrus Microstenting does not result in statistically significant lower IOP compared to the Microstent alone at POM1. Both procedures significantly decrease drop burden at POM1, with the Hydrus/OMNI group achieving a greater drop reduction.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×